| This week, the U.S. Food and Drug Administration expanded emergency use authorization for Pfizer's COVID-19 boosters for children ages 12 to 15.
The agency has also shortened the time needed between the two primary doses of the vaccine and a booster — from six months to five months — for anyone 12 and older.
“Throughout the pandemic, as the virus that causes COVID-19 has continuously evolved, the need for the FDA to quickly adapt has meant using the best available science to make informed decisions with the health and safety of the American public in mind,” FDA Acting Commissioner Dr. Janet Woodcock said in a statement.
The U.S. Centers for Disease Control and Prevention backed the decision to shorten the window between initial doses of Pfizer's vaccine and a booster.
FDA leaders say a rapid increase in cases across the country showed the benefits of expanding booster access outweigh any risks.
“It made sense to move as quickly as we possibly could,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
Read more about this story. |
No comments:
Post a Comment
Keep a civil tongue.